IDP-121 / IDP Pharma - LARVOL DELTA

CASSANDRA: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=37 | Recruiting | Sponsor: IDP Discovery Pharma S.L. | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

IDP Pharma announces first patient dosed in a Phase 1/2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader (PRNewswire) - "IDP Pharma, a clinical-stage biotechnology company pioneering the development of drugs that directly engage and degrade intrinsically disordered proteins (IDPs), today announced that the first patient has been successfully dosed in its IDP-121-001 CASSANDRA trial, a multi-center, open-label Phase I/II study for the treatment of cMyc driven hematological malignancies....The study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of IDP-121."

Trial status • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Multiple Myeloma

CASSANDRA: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=37 | Recruiting | Sponsor: IDP Discovery Pharma S.L. | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: May 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

CASSANDRA: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=37 | Recruiting | Sponsor: IDP Discovery Pharma S.L.

New P1/2 trial • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

[VIRTUAL] IDP-121, a first in class staple peptide targeting c-MYC (AACR 2021) - "Isolated protein complex (ELISA), and pull-down and FRET experiments confirmed disruption of the c-MYC/MAX complex by IDP-121 (see Abstracts 2). The drug-like properties and efficacy in hematological and solid tumors of IDP-121 have been demonstrated in vivo (see Abstracts 2 and 3). In addition, IDP-121 has progressed through GLP toxicology studies without evidence of major systemic toxicity, allowing for the first viable Myc-targeted therapy to enter Phase 1 clinical trials in 2021."

Oncology • Solid Tumor • MYC • MYCN

[VIRTUAL] The novel c-MYC inhibitor IDP-121 exhibits strong anti-myeloma effect (AACR 2021) - "Finally, and importantly, preliminary combination experiments highlight that IDP-121 potentiated the activity of MM standards of care such as bortezomib and dexamethasone.  The results presented here suggest that IDP-121 could be a first-in-class inhibitor of c-MYC in MM. The drug-like properties and efficacy also in solid tumors of IDP-121 have been demonstrated in vivo (see Abstracts 3). In addition, IDP-121 has progressed through GLP toxicology studies without evidence of major systemic toxicity, allowing for the first viable Myc-targeted therapy to enter Phase 1 clinical trials in 2021."

Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma • Solid Tumor • MYC

[VIRTUAL] A first-in-class c-MYC inhibitor shows in vivo efficacy in lung cancer models and has appropriate drug-like characteristics (AACR 2021) - "The efficacy in hematological tumors of IDP-121 have been also demonstrated in vivo (see Abstract 2). In addition, IDP-121 has progressed through GLP toxicology studies without evidence of major systemic toxicity, allowing for the first viable Myc-targeted therapy to enter Phase 1 clinical trials in 2021."

Preclinical • Hematological Malignancies • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • MYC